The humoral immune response to foot-andmouth disease virus (FMDV) in cattle, swine, and other animals after infection or vaccination is characterized by the development of immunoglobulin M and immunoglobulin G antibodies which are capable of neutralizing infectious virus in vitro and in vivo (6, 19 ). In general, the level of circulating neutralizing antibody appears to be related to the degree of protective immunity shown by convalescent and vaccinated animals (7, 11 ; I. Nathans, Ph.D. thesis, Centraal Diergeneeskundig Institut, Amsterdam, 1965) .
Cell-mediated immunity (CMI) has not been reported in foot-and-mouth disease, but in the studies just cited the presence of neutralizing antibodies may have obscured a protective role for CMI. The recent demonstration of CMI in mice infected with coxsackievirus B-3 (20) , also a picornavirus, provides incentives for studying CMI to FMDV. The current study is part of a series aimed at determining the degree to which CMI and humoral immunity can contribute to the protection of various animal species against infection with FMDV.
Guinea pigs were chosen as experimental models with which to develop concepts and techniques to study CMI because of the similarities of clinical symptoms in these animals to those of swine and cattle. Unlike swine or cattle, guinea pigs cannot be infected via respiratory aerosols. However, inoculation with virus into the skin or tongue leads to clinical infection.
The objectives of the present study were to determine whether guinea pigs develop CMI after infection and to determine any differences in the clinical disease or (18) . Virus was inactivated with 0.1% binary ethyleneimine for 24 h at room temperature (4 Inactivation was confirmed by the failure of 10, 1, and 0.1 g of FMDV to infect guinea pigs after intralingual and heel pad inoculation or to cause lysis of MVPK cells. Purified inactivated virus was stored at 5"C.
Animal inoculations. Outbred, female DuncanHartley strain guinea pigs, weighing 300 to 400 g, obtained from this center's colony, were used for all experiments. Guinea pigs were infected with vesicular fluid diluted in phosphate-buffered saline to achieve the appropriate virus concentrations. Ten microliters of vesicular fluid was administered subcutaneously into the phalangeal pads of the right rear foot, intralingually into the anterior dorsal surface of the tongue (13) , intradermally into the shaved flank, and intradermally by tracking virus into the metatarsal pad of the right rear foot (2) . In this last method, two intradermal tracks approximately 1 to 2 cm long were made with a 26-gauge needle, and 5 tl of vesicular fluid was injected into each track as the needle was removed. Blood was inoculated by cardiac puncture with a 0.5-ml suspension of vesicular fluid diluted in phosphatebuffered saline containing 20 protective dose (PD50) assay (8) . Fivefold dilutions of serum were mixed with equal volumes of a virus dilution such that the final mixture contained 100 50% mouse lethal doses per 0.03 ml. The serum-virus mixtures were incubated for 30 min at 37"C. Then 0.03 ml of each mixture was inoculated intraperitoneally into each of eight suckling mice. The numbers of mice surviving after 5 days were used to calculate the PD50, which is the reciprocal of the logarithm,0 of the serum dilution protecting four of the eight suckling mice against 100 50% lethal doses of the virus.
MIF assay. A previously described macrophage migration inhibition factor (MIF) assay (1) was modified as follows. The medium was minimal essential medium with Earle salts supplemented with 25 mM HEPES buffer (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid), 100 U of penicillin per ml, 100
Mg of streptomycin per ml, and 5% fetal calf serum.
Peritoneal exudate cells (PEC) were collected at 4 to 6 days after intraperitoneal injection of 25 ml of Marcol 52. The peritoneal cavity was opened with a midventral incision and ravaged with 50 ml of minimal essential medium containing 5 U of heparin per ml. The PEC were washed twice with minimal essential medium, treated with 0.75% ammonium chloride (pH 7.2) to lyse residual erythrocytes, washed again, counted, and resuspended to 50 x 10" cells per ml. A 60-Md amount of cell suspension was dispensed with a Hamilton syringe (Pierce Chemical Co., Rockford, Ill.) into capillary tubes sealed at one end with Plasticene (Fisher Scientific Co., Pittsburgh, Pa.) and centrifuged at 500 x g for 5 min. The capillary tubes were cut at the cell button-medium interface, and the short piece of capillary tubing containing the cell button was affixed to the inside of a migration inhibition chamber (Mini Lab Co., Ville de Laval, Quebec, Canada) with silicone grease. Each chamber contained two tubes and was sealed at the top with a coverslip and silicone. to 70% of the cases that showed vesicles on the heel pads, the tongue also developed vesicles. Healing of the heel pads, forefeet, and tongue was usually apparent 7 to 10 days after infection. Table 1 shows that all clinically infected animals showed severe signs of disease, except animal no. 3, which developed only a small vesicle on the heel pad of the foot used for infection. Despite this mild form of disease, this animal had an immune response of the same magnitude as the guinea pigs showing generalized lesions.
Neutralizing antibody titers and skin test reactivity of all guinea pigs were assayed at 25 days postinfection (p.i.) (Table 1) . Clinically infected guinea pigs showed high levels of neutralizing antibody and skin reactions characterized by marked induration at both 4 and 24 h. Arthus (4 h) reactivity was usually 20 to 30% higher than the delayed (24 h) reactivity. Arthus reactivity was accompanied by erythema, which was first seen as a pink area 15 to 20 mm in diameter and which deepened in intensity to a red area 20 to 25 mm in diameter at 24 h (data not shown). The persistence of skin test reactivity at 24 h suggested a cell-mediated immune response to FMDV.
When guinea pigs were infected intracardially (data not shown) with the same viral doses shown in Table 1 Figure 1 shows that neutralizing antibody was first detected on day 3 p.i., rose rapidly to a peak on day 6, and subsequently decreased slightly by days 10 and 20. Cowan and Trautman (6) showed that early antibody produced at 5 to 10 days p.i. was immunoglobulin M, which was replaced by immunoglobulin G antibody at 10 to 12 days p.i. In contrast to neutralizing antibody, Arthus reactivity, which primarily detects complement-fixing antibody of the immunoglobulin G2 class (5), was first detected on day 4 and increased to maximum activity on days 10 and 20.
Delayed skin reactivity was also detected as early as day 4 p.i. and on days 4 to 6 was of the same magnitude as the Arthus reactivity. On days 10 and 20, delayed skin reactivity continued to increase. To further suggest a cell-mediated immune response to FMDV, substantial skin reactivity at 48 h could be detected on day 6 and continued to increase until day 20. The fact that MIF activity was detected on day 6 and persisted until day 20 further shows the early development and persistence of CMI to FMDV. From these data, the sequence of immune events appears to start with the initial production of immunoglobulin M on day 3 p.i., followed by low levels of immunoglobulin G production and the concomitant development of CMI on day 4.
Effect of different routes of infection on clinical and immune responses. Guinea pigs infected with 10' PFU of FMDV administered by different routes were observed for their clinical response to infection and then were skintested at 20 days p.i. (Table 3 ). All groups of animals showed strong Arthus reactivity and delayed skin reactivity. Despite the route of infection, no significant differences in the resulting CMI or humoral immunity could be determined. In similar experiments, PEC from animals infected by different routes produced significant amounts of MIF (50% or more migration inhibition) in response to stimulation with inactivated FMDV (data not shown).
Guinea pigs infected subcutaneously, intracardially, or intradermally in the flank skin developed vesicles at 3 to 4 days p.i., whereas intralingual-or heel pad-infected animals developed vesicles at the challenge site within 1 day p.i.; the disease generalized within the next 2 to 3 days. It was noteworthy that three of five animals infected via the flank skin in this experiment showed no (Table 3) ; three of five animals developed subclinical infections. Subclinically infected animals had CMI and humoral immunity of the same magnitude as clinically infected animals. Thus, the antigenic load necessary to induce this level of immunity in subclinically infected animals must be derived from replication of virus at nonvisible sites. Potential replication sites may be inferred from the work of Platt (17), who observed necrosis of the exocrine tissue of the pancreas, occasional necrosis of cardiac fibers, and epithelial lesions in the esophagus, prepuce, ear, and perineal regions of male and pregnant female infected guinea pigs. Subclinical infections with FMDV are not confined to guinea pigs because Henderson et al. (12) have reported inapparent infections in aerosol-infected cattle which resulted in a strong protective immunity.
Protective immunity in subclinically infected guinea pigs may also be related to the type of immunity induced by dose and route; low doses of antigen and intradermal inoculations preferentially stimulate CMI (14) . A study of subclinical infections in guinea pigs may provide additional insights in mechanisms of host resistance to FMDV.
Graves et al. (11) have reported a high level of correlation between the FMDV neutralizing antibody titer induced by vaccination and the protection of cattle from infection. The current finding of a cell-mediated immune response to FMDV in guinea pigs suggests that CMI may also constitute part of the immune response to FMDV in swine and cattle. In addition, results in studies similar to this one might show that skin test sensitivity could be a useful tool in both laboratory and field studies of immunity to FMDV in swine and cattle.
